Otsuka files FDA application for first-in-class ADHD drug
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
Clinical trials found that 77% of patients went into remission after receiving obe-cel
The trial tested six injectable doses and three oral doses over as long as 36 weeks
Deceased donor kidney transplants are time-critical, and it is uncommon to attempt them robotically
Surgical site infections and antimicrobial resistance remain major challenges globally
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
Solventum aims to accelerate innovation in acute wound care, expand its market reach, and deliver enhanced solutions for patients, clinicians, and shareholders
The collaboration aims to make Alzheimer’s biomarker testing more accessible and less intimidating
Subscribe To Our Newsletter & Stay Updated